Assetmark Inc. Buys 7,605 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Assetmark Inc. raised its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2,493.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,910 shares of the medical research company’s stock after acquiring an additional 7,605 shares during the period. Assetmark Inc.’s holdings in Bio-Rad Laboratories were worth $2,599,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Metis Global Partners LLC lifted its stake in Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock valued at $234,000 after acquiring an additional 30 shares in the last quarter. Avior Wealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after purchasing an additional 32 shares during the period. UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after purchasing an additional 32 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the period. Finally, CIBC Asset Management Inc raised its stake in shares of Bio-Rad Laboratories by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock worth $234,000 after purchasing an additional 34 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Trading Up 1.1 %

Shares of Bio-Rad Laboratories stock opened at $260.92 on Monday. Bio-Rad Laboratories, Inc. has a 52-week low of $248.22 and a 52-week high of $387.99. The stock’s 50-day simple moving average is $319.72 and its 200 day simple moving average is $330.35. The stock has a market capitalization of $7.31 billion, a P/E ratio of -4.01 and a beta of 0.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BIO shares. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.